Targeted Therapeutics for Cancer and Ophthalmology

TRC205

TRC205 is a humanized, deimmunized anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases. Diseases characterized by fibrosis, the harmful buildup of excessive fibrous tissue leading to scarring and ultimately organ failure, include NASH, IPF, renal fibrosis, cardiac fibrosis and scleroderma.

TRC205 Scientific Presentations:

2016 AASLD Endoglin Antibodies in NASH and Liver Fibrosis